Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Department of Health has today announced four million pounds to improve the evidence for new diagnostic tests, benefiting patient care. The National Institute for Health Research (NIHR) will share the funding across four NHS organisations, including Oxford.

Every year over 16 million diagnostic tests are carried out across the NHS. This money will fund research that looks at the way a number of different diseases are diagnosed, so patients can access the best available treatments more quickly.

The National Institute for Health Research (NIHR) will share the funding across four NHS organisations in London, Leeds, Newcastle and Oxford. These places will become national centres of expertise called NIHR Diagnostic Evidence Co-operatives.

Dr Matthew Thompson, Director of Oxford Centre for Monitoring and Diagnosis, Department of Primary Care Health Sciences, University of Oxford commented: "We are delighted that the NIHR has selected Oxford as the site that will pioneer research and development into new diagnostic tests in primary care. Together with our partners, which include Oxford Health NHS Foundation Trust, we will bring together the diagnostics industry, frontline clinicians, and researchers to produce new evidence to show which new tests should be used in the NHS. The funding announced by the NIHR will position our Centre as a national resource for diagnostic testing in NHS primary care."

 

Read more

Similar stories

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.

Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.